Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
World game at war: why some European nations have threatened a World Cup boycott 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
LEIDEN, the Netherlands, April 11, 2018 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including Leber's congenital amaurosis 10, dystrophic epidermolysis bullosa and cystic fibrosis, today announced that the Annual General Meeting of Shareholders will be held on Wednesday, May 16, 2018 at 17:00 CET, at the offices of Allen & Overy at Apollolaan 15, 1077 AB Amsterdam, the Netherlands.
All relevant documents and information for the meeting, including the notice and agenda, are or will be made available in the ‘Investor Relations’ section of ProQR’s website (www.proqr.com) under ‘Financial Information’. The documents will also be made available on the SEC's website at www.sec.gov.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as Leber’s congenital amaurosis 10, dystrophic epidermolysis bullosa and cystic fibrosis. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*
ProQR Therapeutics N.V.:
Smital Shah
Chief Financial Officer
T: +1 415 231 6431
[email protected]
